leadf
logo-loader
viewErgomed PLC

Ergomed executive chairman says firm “had a good first quarter, with solid overall growth in revenue”

Dr Miroslav Reljanović added: “At this time the Company is confident that results will be in line with current market expectations for the 2020 financial year”

Ergomed PLC -
Ergomed is focused on providing specialised services to the pharmaceutical industry

Ergomed PLC (LON:ERGO) executive chairman, Dr Miroslav Reljanović has told shareholders in advance of Wednesday’s closed annual general meeting that the company, which is focused on providing specialised services to the pharmaceutical industry, “had a good first quarter, with solid overall growth in revenue.”

In a statement released ahead of the AGM, Reljanović said: “Following the outbreak of (coronavirus) COVID-19 in March 2020, the Company has successfully transferred to a fully remote working operation with minimal disruption and no redundancies or furloughed staff.”

READ: Ergomed’s PrimeVigilance inks collaboration deal to accelerate intelligent automation strategy

The executive chairman added: "The Company has continued to make good strategic progress this year, with further integration of the combined business under the pharmaceutical services model. The Ashfield Pharmacovigilance business, acquired in January 2020, has been integrated in line with plans as PrimeVigilance USA, providing significant commercial benefit to the group overall. Cash generation remains strong, and the Company is in a robust financial position. 

"Despite the impact of COVID-19 on the general business environment, in the second quarter of 2020 the Company has continued to grow its order book across the business and to maintain its revenue growth trend whilst implementing effective cost control measures. The Company is confident in the performance of the business for the first half of 2020."

He concluded: "In line with our usual practice, in July 2020 the Company will provide an update on current trading and the outlook for the remainder of the current financial year ending 31 December 2020.

“At this time the Company is confident that results will be in line with current market expectations for the 2020 financial year.”

Quick facts: Ergomed PLC

Price: 930 GBX

AIM:ERGO
Market: AIM
Market Cap: £453.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE fights back after bruising start to week

The FTSE is fighting back after enduring the worst sell-off since June on Monday.  UK Prime Minister Boris Johnson will address the nation today about more possible lockdowns after announcing pubs, bars, restaurants and other hospitality venues in England must close by...

on 22/9/20

2 min read